Pediatric langerhans cell histiocytosis: single center experience over a 17-year period

Turkish Journal of Pediatrics - Tập 58 Số 4 - Trang 349-355
Dilek İnce1, Selcen Kundak2, Yöntem Yaman3, Serra Kamer4, Yeşim Oymak3, Ragıp Ortaç5, Ayşe Erbay6, Gülcihan Özek3, Bengü Demirağ3, Canan Vergin3
1Department of Pediatric Oncology, Dokuz Eylül University Institute of Oncology, İzmir.
2Dermatology Clinic, Dr Behçet Uz Children's Hospital, İzmir.
3Department of Pediatric Hematology-Oncology Clinic, Dokuz Eylül University Institute of Oncology, İzmir.
4Department of Radiation Oncology, Ege University Faculty of Medicine, İzmir.
5Department of Pathology, İzmir University Faculty of Medicine, İzmir.
6Division of Pediatric Oncology, Başkent University Faculty of Medicine, Adana, Turkey.

Tóm tắt

This study aimed to analyze children with the diagnosis of Langerhans cell histiocytosis (LCH) who were diagnosed and treated between 1998-2015. Medical records were evaluated retrospectively for clinical and laboratory features, treatment details, and outcome. There were 20 patients, the median age of diagnosis was 37 months, M/F ratio: 1.5. Nine had single system (SS), 11 had multisystem (MS) LCH. Spontaneous regression occurred in three infants with skin limited LCH. Eight patients had risk organ involvement in MS-LCH group. The curettage alone was performed in only one case. Patients received LCH-II/ LCH-III based chemotherapy schema. Radiotherapy was performed to vertebral disease and residual craniofacial bone disease in four cases. The regression and relapse rates were 100% and 33% for SS-LCH. The regression and relapse rates were 73%, and 18% for MS-LCH. Two infants with MS-LCH died despite chemotherapy. Pulmonary and liver involvements affected outcome adversely in MS-LCH. Multidisciplinary treatment approaches are needed.

Từ khóa


Tài liệu tham khảo

Thông tin
Thông tin xuất bản

Turkish Journal of Pediatrics

Tập 58 Số 4

349-355

Thông tin tác giả